
## David Boutolleau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2108201/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Herpes simplex virus, varicella-zoster virus and cytomegalovirus keratitis: Facts for the clinician. Ocular Surface, 2023, 28, 336-350.	2.2	11
2	Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers. Clinical Infectious Diseases, 2022, 74, 707-710.	2.9	10
3	Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient. Current Research in Translational Medicine, 2022, 70, 103329.	1.2	2
4	Acyclovir-Resistant Herpes Simplex Virus 1 Keratitis: A Concerning and Emerging Clinical Challenge. American Journal of Ophthalmology, 2022, 238, 110-119.	1.7	15
5	Preemptive acyclovir to prevent herpes simplex virus bronchopneumonitis in mechanically ventilated patients with herpes simplex virus oropharyngeal reactivation: An ancillary study of the preemptive treatment for herpesviridae trial. Antiviral Therapy, 2022, 27, 135965352110726.	0.6	0
6	Pritelivir for recurrent aciclovir-resistant herpes simplex virus 2 infections in immunocompromised patients. Journal of Antimicrobial Chemotherapy, 2022, 77, 2303-2305.	1.3	12
7	Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19. Journal of Infection, 2021, 82, 159-198.	1.7	14
8	Co-infection of SARS-CoV-2 with other respiratory viruses and performance of lower respiratory tract samples for the diagnosis of COVID-19. International Journal of Infectious Diseases, 2021, 102, 10-13.	1.5	46
9	Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nature Communications, 2021, 12, 844.	5.8	146
10	Association between cytomegalovirus infection and allograft rejection in a large contemporary cohort of heart transplant recipients. Transplant Infectious Disease, 2021, 23, e13569.	0.7	6
11	Immediate Impact of Induction Treatment on Postvaccination SARS-CoV-2 Serology in Kidney Transplant Recipients. Transplantation, 2021, 105, e135-e136.	0.5	3
12	Post-herpetic encephalitis cerebral abscess: Viral reactivation or latency site within central nervous system?. Current Research in Translational Medicine, 2021, 69, 103297.	1.2	0
13	High conservation of varicella-zoster virus helicase-primase complex, the target of the new antiviral drug amenamevir. Antiviral Research, 2021, 195, 105189.	1.9	1
14	Meningitis Caused by the Live Varicella Vaccine Virus: Metagenomic Next Generation Sequencing, Immunology Exome Sequencing and Cytokine Multiplex Profiling. Viruses, 2021, 13, 2286.	1.5	11
15	Diagnostic challenges of central nervous system infection: extensive multiplex panels versus stepwise guided approach. Clinical Microbiology and Infection, 2020, 26, 706-712.	2.8	28
16	Characterization of the dynamics of human cytomegalovirus resistance to antiviral drugs by ultra-deep sequencing. Antiviral Research, 2020, 173, 104647.	1.9	15
17	Retrospective Observational Study of Brain MRI Findings in Patients with Acute SARS-CoV-2 Infection and Neurologic Manifestations. Radiology, 2020, 297, E313-E323.	3.6	131
18	Caution is required for the interpretation of mutations in herpes simplex virus DNA polymerase for resistance to acyclovir. Journal of Global Antimicrobial Resistance, 2020, 22, 695-696.	0.9	0

#	Article	IF	CITATIONS
19	Arguments to Support a Viral Origin of Oral Squamous Cell Carcinoma in Non-Smoker and Non-Drinker Patients. Frontiers in Oncology, 2020, 10, 822.	1.3	19
20	The First Locally Acquired Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Healthcare Worker in the Paris Area. Clinical Infectious Diseases, 2020, 71, e530-e531.	2.9	6
21	FRI0157â€EPSTEIN BARR VIRUS BLOOD REPLICATION INCREASES DURING ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases, 2020, 79, 662.3-662.	0.5	Ο
22	Added value of ultra-deep sequencing (UDS) approach for detection of genotypic antiviral resistance of herpes simplex virus (HSV). Antiviral Research, 2019, 168, 128-133.	1.9	8
23	Input of recombinant phenotyping for the characterization of a novel acyclovir-resistance mutation identified in a patient with recurrent herpetic keratitis. Antiviral Research, 2019, 168, 183-186.	1.9	7
24	Comparison of Anti-Viral Activity of Frog Skin Anti-Microbial Peptides Temporin-Sha and [K3]SHa to LL-37 and Temporin-Tb against Herpes Simplex Virus Type 1. Viruses, 2019, 11, 77.	1.5	32
25	Utility of ultra-deep sequencing for detection of varicella-zoster virus antiviral resistance mutations. Antiviral Research, 2018, 151, 20-23.	1.9	12
26	Procalcitonin for clinical decisions on influenza-like illness in emergency department during influenza a(H1N1)2009 pandemic. Biomarkers, 2018, 23, 10-13.	0.9	7
27	Antiviral effects of Cacicol®, a heparan sulfate biomimetic for corneal regeneration therapy, for herpes simplex virus type-1 and varicella zoster virus infection. Antiviral Therapy, 2018, 23, 665-675.	0.6	7
28	Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016. BMC Infectious Diseases, 2018, 18, 331.	1.3	27
29	Antivirales (a excepción del VIH y la hepatitis). EMC - Tratado De Medicina, 2017, 21, 1-10.	0.0	1
30	Ancient Recombination Events between Human Herpes Simplex Viruses. Molecular Biology and Evolution, 2017, 34, 1713-1721.	3.5	49
31	Recurrent herpetic keratitis despite antiviral prophylaxis: A virological and pharmacological study. Antiviral Research, 2017, 146, 205-212.	1.9	32
32	A European multi-centre External Quality Assessment (EQA) study on phenotypic and genotypic methods used for Herpes Simplex Virus (HSV) drug resistance testing. Journal of Clinical Virology, 2017, 96, 89-93.	1.6	13
33	Genotypic resistance of cytomegalovirus to antivirals in hematopoietic stem cell transplant recipients from Portugal: A retrospective study. Antiviral Research, 2017, 138, 86-92.	1.9	10
34	Prise en charge thérapeutique des infections à herpÃ <sup>~</sup> svirus : traitements actuels et futurs. Revue Francophone Des Laboratoires, 2016, 2016, 55-64.	0.0	0
35	Complementary assays for monitoring susceptibility of varicella-zoster virus resistance to antivirals. Journal of Virological Methods, 2016, 233, 10-14.	1.0	8
36	Herpes simplex virus type 2: Cluster of unrelated cases in an intensive care unit. American Journal of Infection Control, 2016, 44, 1178-1180.	1.1	2

#	Article	IF	CITATIONS
37	Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art. Reviews in Medical Virology, 2016, 26, 161-182.	3.9	53
38	Infections à cytomégalovirus en transplantationÂ: manifestations cliniques, diagnostic virologique et prise en charge thérapeutique. Journal Des Anti-infectieux, 2016, 18, 70-78.	0.1	0
39	Atypical ocular manifestation of primary varicella zoster virus infection as the first manifestation of AIDS. Aids, 2016, 30, 674-676.	1.0	1
40	Adenovirus related lymphohistiocytic hemophagocytosis: Case report and literature review. Journal of Clinical Virology, 2016, 78, 53-56.	1.6	10
41	Determinants of a Low CD4/CD8 Ratio in HIV-1–Infected Individuals Despite Long-term Viral Suppression. Clinical Infectious Diseases, 2016, 62, 1297-1303.	2.9	64
42	High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies. Antiviral Research, 2016, 128, 1-6.	1.9	7
43	Management of Multidrug-Resistant CMV Infection in Immunocompromised Patients: Case Report of a Heart-Transplant Recipient and Review of the Literature. Antiviral Therapy, 2015, 20, 249-254.	0.6	12
44	External quality assessment for herpes simplex virus Drug Resistance Testing: A French Feasibility Study. Journal of Clinical Virology, 2015, 70, S110.	1.6	0
45	Impact of HIVâ€1 infection on herpes simplex virus type 2 genetic variability among coâ€infected individuals. Journal of Medical Virology, 2015, 87, 357-365.	2.5	5
46	Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients. Transplant Infectious Disease, 2015, 17, 822-830.	0.7	72
47	Tenofovir Gel to Prevent HSV-2 Infection. New England Journal of Medicine, 2015, 373, 1980-1981.	13.9	1
48	Genetic Diversity within Alphaherpesviruses: Characterization of a Novel Variant of Herpes Simplex Virus 2. Journal of Virology, 2015, 89, 12273-12283.	1.5	21
49	Low Titers of Serum Antibodies Inhibiting Hemagglutination Predict Fatal Fulminant Influenza A(H1N1) 2009 Infection. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1240-1249.	2.5	26
50	Helicase–Primase Inhibitor Pritelivir for HSV-2 Infection. New England Journal of Medicine, 2014, 370, 1663-1664.	13.9	3
51	Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection. International Journal of STD and AIDS, 2014, 25, 676-682.	0.5	5
52	Validation of the QIAsymphony RGQ system for DNA quantitation of different BK virus genotypes in whole blood samples. Journal of Virological Methods, 2014, 196, 32-35.	1.0	3
53	Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. Antiviral Research, 2014, 111, 8-12.	1.9	22
54	Cytomegalovirus Infection in Patients Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation in Portugal: A Five-Year Retrospective Review. Biology of Blood and Marrow Transplantation, 2014, 20, 1958-1967.	2.0	41

#	Article	IF	CITATIONS
55	Resistance of herpes simplex viruses to acyclovir: An update from a ten-year survey in France. Antiviral Research, 2014, 111, 36-41.	1.9	120
56	Acyclovir-resistant varicella-zoster virus keratitis in an immunocompetent patient. Journal of Clinical Virology, 2013, 58, 318-320.	1.6	14
57	Detection of a new variant of herpes simplex virus type 2 among HIV-1-infected individuals. Journal of Clinical Virology, 2013, 57, 267-269.	1.6	12
58	Phenotypic and genotypic characterization of acyclovir-resistant corneal HSV-1 isolates from immunocompetent patients with recurrent herpetic keratitis. Journal of Clinical Virology, 2013, 58, 321-324.	1.6	33
59	Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey. Antiviral Research, 2013, 100, 365-372.	1.9	58
60	Temporal and Spatial Compartmentalization of Drug-Resistant Cytomegalovirus (CMV) in a Child with CMV Meningoencephalitis: Implications for Sampling in Molecular Diagnosis. Journal of Clinical Microbiology, 2013, 51, 4266-4269.	1.8	26
61	Molecular Characterization of Herpes Simplex Virus 2 Strains by Analysis of Microsatellite Polymorphism. Journal of Clinical Microbiology, 2013, 51, 3616-3623.	1.8	25
62	Routine use of duplex real-time PCR assays including a commercial internal control for molecular diagnosis of opportunistic DNA virus infections. Journal of Virological Methods, 2012, 185, 136-141.	1.0	17
63	Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection. Journal of Clinical Virology, 2012, 54, 194-196.	1.6	10
64	Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity. Antiviral Research, 2012, 96, 386-390.	1.9	29
65	Clinical and Microbiological Evaluation of Travel-Associated Respiratory Tract Infections in Travelers Returning From Countries Affected by Pandemic A(H1N1) 2009 Influenza. Journal of Travel Medicine, 2012, 19, 22-27.	1.4	12
66	Genotypic characterization of herpes simplex virus DNA polymerase UL42 processivity factor. Antiviral Research, 2012, 93, 199-203.	1.9	7
67	Confirmation of the low clinical effect of human herpesvirusâ€6 and â€7 infections after renal transplantation. Journal of Medical Virology, 2012, 84, 450-456.	2.5	19
68	Infections à cytomégalovirus humain en transplantationÂ: diagnostic virologique et traitement antiviral. Journal Des Anti-infectieux, 2011, 13, 238-245.	0.1	0
69	A fatal case of Human Herpesvirus 6 chronic myocarditis in an immunocompetent adult. Journal of Clinical Virology, 2011, 52, 142-145.	1.6	40
70	Human NKG2A overrides NKG2C effector functions to prevent autoreactivity of NK cells. Blood, 2011, 117, 4394-4396.	0.6	29
71	Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. Antiviral Research, 2011, 91, 32-35.	1.9	18
72	Rapid Virological Diagnosis of Central Nervous System Infections by Use of a Multiplex Reverse Transcription-PCR DNA Microarray. Journal of Clinical Microbiology, 2011, 49, 3874-3879.	1.8	49

#	Article	IF	CITATIONS
73	Exhausted Cytotoxic Control of Epstein-Barr Virus in Human Lupus. PLoS Pathogens, 2011, 7, e1002328.	2.1	111
74	Conservation of HHV-6 DNA polymerase processivity factor sequence and predicted structure suggests it as a target for antiviral development. Antiviral Research, 2010, 86, 316-319.	1.9	2
75	Detection of Pandemic (H1N1) 2009 Virus in Patients Treated with Oseltamivir. Emerging Infectious Diseases, 2010, 16, 351-352.	2.0	3
76	Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. Journal of Antimicrobial Chemotherapy, 2010, 65, 2628-2640.	1.3	141
77	Genotypic Characterization of UL23 Thymidine Kinase and UL30 DNA Polymerase of Clinical Isolates of Herpes Simplex Virus: Natural Polymorphism and Mutations Associated with Resistance to Antivirals. Antimicrobial Agents and Chemotherapy, 2010, 54, 4833-4842.	1.4	111
78	Bipolar Hypertrophic Herpes: An Unusual Presentation of Acyclovir-Resistant Herpes Simplex Type 2 in a HIV-Infected Patient. Sexually Transmitted Diseases, 2010, 37, 126-128.	0.8	21
79	Microsatellite analysis of HSV-1 isolates: From oropharynx reactivation toward lung infection in patients undergoing mechanical ventilation. Journal of Clinical Virology, 2010, 47, 313-320.	1.6	16
80	Testing the susceptibility of human herpesviruses to antivirals. Future Microbiology, 2009, 4, 1111-1123.	1.0	13
81	Utilization of Microsatellite Polymorphism for Differentiating Herpes Simplex Virus Type 1 Strains. Journal of Clinical Microbiology, 2009, 47, 533-540.	1.8	68
82	Length variability of telomeric repeat sequences of human herpesvirus 6 DNA. Journal of Virological Methods, 2009, 159, 127-130.	1.0	34
83	Use of the Roche LightCycler® 480 system in a routine laboratory setting for molecular diagnosis of opportunistic viral infections: Evaluation on whole blood specimens and proficiency panels. Journal of Virological Methods, 2009, 159, 291-294.	1.0	15
84	Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. Antiviral Research, 2009, 81, 174-179.	1.9	44
85	Different expression of human herpesvirus-6 (HHV-6) load in whole blood may have a significant impact on the diagnosis of active infection. Journal of Clinical Virology, 2009, 46, 33-36.	1.6	17
86	PIX-3 Cytomegalovirus (CMV) resistance to antivirals in children and adult hematopoietic stem cell transplant recipients from the Czech Republic – a two centres experience. Journal of Clinical Virology, 2009, 46, S44.	1.6	0
87	Genetic analysis and putative role in resistance to antivirals of the human cytomegalovirus DNA polymerase UL44 processivity factor. Antiviral Therapy, 2009, 14, 847-852.	0.6	6
88	Human herpesvirusâ€6 infection: A prospective study evaluating HHVâ€6 DNA levels in liver from children with acute liver failure. Journal of Medical Virology, 2008, 80, 1051-1057.	2.5	44
89	Characterization of a cidofovir-resistant HHV-6 mutant obtained by in vitro selection. Antiviral Research, 2008, 77, 237-240.	1.9	31
90	Multicenter Comparison of PCR Assays for Detection of Human Herpesvirus 6 DNA in Serum. Journal of Clinical Microbiology, 2008, 46, 2700-2706.	1.8	73

#	Article	IF	CITATIONS
91	Surgical treatment of a foscavir-resistant atypical Cytomegalovirus pneumonia in an allogeneic stem cell transplant recipient. Haematologica, 2008, 93, e39-e41.	1.7	2
92	Human herpesvirus-6 (HHV-6) DNA in plasma reflects the presence of infected blood cells rather than circulating viral particles. Journal of Clinical Virology, 2007, 38, 280-285.	1.6	66
93	Human herpesvirus 6-associated retrobulbar optic neuritis in an HIV-infected patient: response to anti-herpesvirus therapy and long-term outcome. Journal of Medical Virology, 2007, 79, 931-934.	2.5	17
94	Different Mutations in the HHV-6 DNA Polymerase Gene Accounting for Resistance to Foscarnet. Antiviral Therapy, 2007, 12, 877-888.	0.6	35
95	5: In vitro analysis of human herpesvirus 6 (HHV-6) infection of polymorphonuclear leukocytes. Journal of Clinical Virology, 2006, 37, S98.	1.6	0
96	9: Human herpesvirus 6 variants A and B (HHV-6A and HHV-6B) exhibit different tropism for human fibroblasts. Journal of Clinical Virology, 2006, 37, S99.	1.6	0
97	17: Specific detection and quantification of human herpesvirus 6 (HHV-6) variants A and B. Journal of Clinical Virology, 2006, 37, S101.	1.6	0
98	61: In vitro selection and characterization of human herpesvirus 6 strains resistant to foscarnet or cidofovir. Journal of Clinical Virology, 2006, 37, S113-S114.	1.6	1
99	Identification of human herpesvirus 6 variants A and B by primer-specific real-time PCR may help to revisit their respective role in pathology. Journal of Clinical Virology, 2006, 35, 257-263.	1.6	95
100	Fatal HHV-6 associated encephalitis in an HIV-1 infected patient treated with cidofovir. Journal of Infection, 2006, 52, 237-242.	1.7	20
101	Is Human Herpesvirus–6 DNA in Plasma the Right Marker for Active Infection?. Journal of Infectious Diseases, 2006, 194, 1795-1796.	1.9	13
102	Human Herpesvirus 6 Genome Integration: A Possible Cause of Misdiagnosis of Active Viral Infection?. Journal of Infectious Diseases, 2006, 194, 1019-1020.	1.9	14
103	Polymorphonuclear Leukocytes Mainly Contribute to Human Herpesvirus–6 Load in the Peripheral Blood of Patients. Clinical Infectious Diseases, 2006, 42, 1342-1343.	2.9	12
104	Persistence of DNA in cell cultures may jeopardize the analysis of human herpesvirus 6 dynamics by means of real-time PCR. Journal of Virological Methods, 2005, 125, 95-98.	1.0	9
105	Detection of human herpesvirus 7 DNA in peripheral blood reflects mainly CD4+ cell count in patients infected with HIV. Journal of Medical Virology, 2005, 76, 223-228.	2.5	22
106	Reactivation of human herpesvirus 6 during ex vivo expansion of circulating CD34+ haematopoietic stem cells. Journal of General Virology, 2004, 85, 3333-3336.	1.3	26
107	An Anti-apoptotic Viral Protein That Recruits Bax to Mitochondria. Journal of Biological Chemistry, 2004, 279, 22605-22614.	1.6	111
108	Is human herpesvirus-7 a marker or a competitor for HIV progression?. Aids, 2004, 18, 358-359.	1.0	8

#	Article	IF	CITATIONS
109	Quantification génomique : applications aux infections par les sixième et septième herpèsvirus humains (HHV-6, HHV-7). Revue Francaise Des Laboratoires, 2003, 2003, 47-48.	0.0	Ο
110	Détection, quantification et analyse des génomes viraux dans les infections à herpèsvirus humains 6Âet 7 (HHV-6, HHV-7). Immuno-Analyse Et Biologie Specialisee, 2003, 18, 191-198.	0.0	1
111	Human Herpesvirus (HHV)–6 and HHV–7: Two Closely Related Viruses with Different Infection Profiles in Stem Cell Transplantation Recipients. Journal of Infectious Diseases, 2003, 187, 179-186.	1.9	132
112	Positive Regulation of CXCR4 Expression and Signaling by Interleukin-7 in CD4 + Mature Thymocytes Correlates with Their Capacity To Favor Human Immunodeficiency X4 Virus Replication. Journal of Virology, 2003, 77, 5784-5793.	1.5	68
113	No Evidence for a Major Risk of Roseolovirus Vertical Transmission During Pregnancy. Clinical Infectious Diseases, 2003, 36, 1634-1635.	2.9	12
114	Real-Time PCR as a Versatile Tool for Investigating the Susceptibility of Human Herpesvirus 6 to Antiviral Agents. Antimicrobial Agents and Chemotherapy, 2003, 47, 3021-3024.	1.4	20
115	Quantitation of HHV-7 genome by real-time polymerase chain reaction assay using MGB probe technology. Journal of Virological Methods, 2002, 106, 11-16.	1.0	50
116	Poor lymphocyte recovery following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. British Journal of Haematology, 1999, 105, 349-360.	1.2	39